Drug intelligence / Profile preview

propofol + remifentanil + vecuronium

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Intravenous
01

Overview

This is a combination of three intravenous agents commonly used in anesthesia practice: - **Propofol** is a short-acting sedative-hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor, producing sedation and hypnosis. It is widely used for induction and maintenance of general anesthesia due to its rapid onset and recovery profile[3]. - **Remifentanil** is an ultra-short acting synthetic opioid analgesic that acts as a potent agonist at the mu-opioid receptor, providing profound analgesia. Its rapid metabolism allows for precise control during surgical procedures[4][7]. - **Vecuronium** is a nondepolarizing neuromuscular blocking agent (muscle relaxant) that competitively inhibits acetylcholine at nicotinic receptors on the motor endplate, resulting in skeletal muscle relaxation necessary for intubation and surgery[6]. The combination of these three drugs provides hypnosis (propofol), analgesia (remifentanil), and muscle relaxation (vecuronium), which are essential components of balanced general anesthesia. This regimen allows for rapid induction, titratable maintenance, quick recovery after cessation, and optimal conditions for airway management and surgery[1][2]. The drugs are typically administered intravenously via separate infusions or boluses; while propofol-remifentanil mixtures have been studied for convenience in total intravenous anesthesia (TIVA), vecuronium must be given separately due to incompatibility with lipid emulsions like propofol's formulation[1][5].

02

Targets

Nicotinic Acetylcholine ReceptorMOR (Mu opioid receptor)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on propofol + remifentanil + vecuronium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + remifentanil + vecuronium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call